

Media Release, January 13, 2017

## **BB Biotech AG with loss in the business year 2016**

In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for the business year 2016.

After a very volatile year of the biotechnology stock market BB Biotech AG closed the business year 2016 based on preliminary unaudited consolidated results with a loss of approximately CHF 802 million (CHF 653 million profit in the previous year).

BB Biotech's share price increased 0.3% in CHF and 1.9% in EUR during the business year 2016.

As an investment company, the results reflect the performance of the stocks it holds in its investment portfolio.

The publication of the Portfolio will take place on January 20, 2017 and the complete Annual Report will be published on February 17, 2017.

### **For further information:**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland  
Tanja Chicherio, Tel. +41 44 267 67 07, [tch@bellevue.ch](mailto:tch@bellevue.ch)

**[www.bbbiotech.com](http://www.bbbiotech.com)**

### **Company profile**

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.